Floatz logo

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE

Vertebral Column Disorder

Grünenthal GmbHSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Vertebral Column Disorder cohort.

Asset / SponsorPhaseRating
Oxycodone
Grünenthal GmbH
Phase 4BBB
Dinitrogen Monoxide
Medical College of Wisconsin
Phase 4BB
Dexmedetomidine
Medical College of Wisconsin
Phase 4BB
Nepenthe
MedtronicNeuro
Phase 4BB
Lidocaine
Medical College of Wisconsin
Phase 4BB

View all 39 →

Same molecule, other indications

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE is also rated in:

chronic pain syndromeActive
BB
Indicative · Phase 4
70 / 100
View asset →
opiate dependenceDormant
BB
Indicative · Phase 4
69 / 100
View asset →
constipation disorderDormant
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →